Dr. Alexey Khrenov received his Ph.D. in Biochemistry from the Institute of Biochemical Physics of Russian Academy of Sciences in Moscow, Russia and is currently CMC reviewer in the Division of Plasma Protein Therapeutics (DPPT), in the Office of Tissues and Advanced Therapies (OTAT) in CBER/ FDA. His review responsibilities include review CMC sections of marketing and investigational applications and supplements for plasma-derived and recombinant hemostatic products. Dr. Khrenov also participated in multiple pre-license and surveillance inspections of manufacturing facilities. Prior to joining the FDA Dr. Khrenov worked at the American Red Cross Holland Laboratory, United States Pharmacopeia and National Institutes of Health. He has been with the FDA for 5 years.